Yi Yang1, Ming Xiao2, Ying Song1, Yi Tang2, Ting Luo1, Shumin Yang1, Wenwen He1, Qingfeng Cheng1, Linqiang Ma1, Yao Zhang3, Yunfeng He3, Youde Cao2, Jun Yang4, Bin Peng5, Jinbo Hu6, Qifu Li7. 1. Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. 3. Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 4. Cardiovascular Endocrinology Laboratory, Hudson Institute of Medical Research, Clayton, Vic, Australia. 5. School of Public Health and Management, Chongqing Medical University, Chongqing, China. 6. Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. hujinbo_568@163.com. 7. Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. liqifu@yeah.net.
Abstract
PURPOSE: To assess the diagnostic performance of the H-score of 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the histopathological diagnosis of adrenocortical tumors (ACT). METHODS: We retrospectively evaluated 199 cases of ACT, of which 85 were diagnosed as aldosterone-producing adenoma (APA), 66 as cortisol-producing adenoma (CPA), 9 as aldosterone-cortisol co-secreting adenoma, 30 as nonhyperfunctioning adenoma, and 9 as adrenocortical carcinoma (ACC). Immunohistochemical staining was performed using anti-CYP11B1 and anti-CYP11B2 monoclonal antibodies. The staining was quantified by the McCarty's H-score system. The diagnostic performance was assessed by the receiver operating characteristic curve (ROC). RESULTS: The H-score of CYP11B1 is highest in the CPA group and lowest in the ACC group. The H-score of CYP11B2 in the APA group is significantly higher than other ACT groups. The area under ROC (AUC) of an increased H-score of CYP11B2 (>65) for the diagnosis of APA was 0.971 (95%CI 0.937-0.990). The AUC of an increased H-score of CYP11B1 (>204) for the diagnosis of CPA was 0.725 (95%CI 0.658-0.786). The AUC of a decreased H-score of CYP11B1 (<85) for the diagnosis of ACC was 0.960 (95%CI 0.923-0.983). CONCLUSIONS: H-score of CYP11B1 and CYP11B2 are reliable tools for the histopathological subtyping of functional benign ACT and may offer some value in the histopathological diagnosis of malignant ACT.
PURPOSE: To assess the diagnostic performance of the H-score of 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the histopathological diagnosis of adrenocortical tumors (ACT). METHODS: We retrospectively evaluated 199 cases of ACT, of which 85 were diagnosed as aldosterone-producing adenoma (APA), 66 as cortisol-producing adenoma (CPA), 9 as aldosterone-cortisol co-secreting adenoma, 30 as nonhyperfunctioning adenoma, and 9 as adrenocortical carcinoma (ACC). Immunohistochemical staining was performed using anti-CYP11B1 and anti-CYP11B2 monoclonal antibodies. The staining was quantified by the McCarty's H-score system. The diagnostic performance was assessed by the receiver operating characteristic curve (ROC). RESULTS: The H-score of CYP11B1 is highest in the CPA group and lowest in the ACC group. The H-score of CYP11B2 in the APA group is significantly higher than other ACT groups. The area under ROC (AUC) of an increased H-score of CYP11B2 (>65) for the diagnosis of APA was 0.971 (95%CI 0.937-0.990). The AUC of an increased H-score of CYP11B1 (>204) for the diagnosis of CPA was 0.725 (95%CI 0.658-0.786). The AUC of a decreased H-score of CYP11B1 (<85) for the diagnosis of ACC was 0.960 (95%CI 0.923-0.983). CONCLUSIONS: H-score of CYP11B1 and CYP11B2 are reliable tools for the histopathological subtyping of functional benign ACT and may offer some value in the histopathological diagnosis of malignant ACT.
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: T Kawamoto; Y Mitsuuchi; K Toda; K Miyahara; Y Yokoyama; K Nakao; K Hosoda; Y Yamamoto; H Imura; Y Shizuta Journal: FEBS Lett Date: 1990-09-03 Impact factor: 4.124
Authors: M Terzolo; A Stigliano; I Chiodini; P Loli; L Furlani; G Arnaldi; G Reimondo; A Pia; V Toscano; M Zini; G Borretta; E Papini; P Garofalo; B Allolio; B Dupas; F Mantero; A Tabarin Journal: Eur J Endocrinol Date: 2011-04-06 Impact factor: 6.664
Authors: D A Budwit-Novotny; K S McCarty; E B Cox; J T Soper; D G Mutch; W T Creasman; J L Flowers; K S McCarty Journal: Cancer Res Date: 1986-10 Impact factor: 12.701